In this retrospective study, we evaluated the predictability of PBSC dose for hematopoietic engraftment comparing that calculated by ideal body weight (IBW) vs another calculated by actual body weight (ABW) for each patient. Sixty-three consecutive patients treated similarly using one transplant protocol were analyzed. While all patients had data available on CFU-GM and nucleated cells (NC), data on CD34
products minimize the chief side-effects of HDC by fast reconstitution of hematopoiesis. In early studies, the PBSC product was evaluated prospectively by total number of nucleated or mononuclear cells and retrospectively by CFU-GM per kilogram of actual body weight, the value of which is known to correlate with days to engraftment of platelets (PLT) and absolute granulocyte counts (AGC). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Presently, the stem cell product is characterized in most laboratories by the number of CD34 + , CFU-GM, and total mononuclear cells per kilogram patient actual body weight (ABW). 1, [17] [18] [19] [20] The number of CD34 + cells correlates well with CFU-GM content and serves as a better predictor of engraftment than total mononuclear cells per kilogram of ABW. 21, 22 Recent evidence suggests that markers of primitive hematopoietic progenitors such as CD34 + /CD33 − and CD34 + /CD38 − as well as others may continue to improve the evaluation of the stem cell product and its predictive value of rapid and sustained hematopoietic recovery. 23, 24 The main impact for this and other improvements in the collection of PBSC will be to reduce patient morbidity by ensuring rapid engraftment, particularly of platelets, and reduce costs by preventing unnecessary apheresis procedures. Recent reports have indicated that the use of greater than 5 × 10 6 CD34 + cells/kg of ABW will result in a significantly shorter time to platelet engraftment, 2 thus reducing the number of platelet transfusions and the related morbidity. However, in order to achieve such a cell dose, more apheresis procedures will be required which in turn increase the cost of peripheral blood stem cell transplantation. 2 Although improvements to date have increased our ability to predict early hematopoietic engraftment, to our knowledge no one has evaluated the influence of body weight on PBSC enumeration and engraftment. It was suggested by some studies 25, 26 but not others 13, 27, 28 that obese individuals have greater PBSC yields. The explanation for such variability remains poorly understood and it could be related to different rates of metabolism of growth factors or an artifact of the cell dose calculation in obese patients. In the United States, it is common knowledge that approximately 40% of the population is overweight and therefore the difference in PBSC dose when calculated by ideal body weight (IBW) vs ABW may be significant. Perhaps calculation of the stem cell dose per IBW may yield a more precise predictor of early engraftment than ABW. If the ability of the PBSC product to reconstitute hematopoiesis is a function of intramedullary bone marrow volume and bone marrow volume is not a function of a patient's pannus, we predict IBW might be a more precise variable to use in the calculation. However, if total blood volume is an important variable in the PBSC product ability to generate hematopoietic recovery, then ABW may be a better measure to use in PBSC dose calculation. In a survey for the purpose of this study, we found that nine of 10 major bone marrow transplant centers use actual body weight for the calculation of the PBSC dose. Therefore, in this study, we have evaluated the predictability of PBSC dose for hematopoietic engraftment comparing that calculated by IBW vs another calculated by ABW for each patient. We report that cell dose per kg IBW is as good or better a predictor of engraftment of AGC and PLT than that PBSC dose calculated per kg ABW and may lead to cost savings in a certain subset of patients.
Materials and methods
Sixty-three consecutive patients with stage II-IV breast cancer, relapsed or refractory Hodgkin's or non-Hodgkin's lymphoma were treated with HDC and PBSC support between 1993 and 1996. The HDC protocols used were approved by the Institutional Review Board and patients gave written informed consent. Although 51 other patients were transplanted between 1996 and the time this manuscript was prepared, the treatment of these patients was not similar in terms of target cell for harvest, use of different growth factors or different starting day post-transplant, use of selected CD34
+ cells for transplantation, and use of different conditioning regimens. Because of these reasons, we were left with the 63 patients as the largest group of patients treated similarly to be used for the current analysis. Patient characteristics are shown in Table 1 . All patients with measurable disease were responsive to chemotherapy at the time of HDC. Parameters obtained for retrospective review included: patient ABW and IBW at the time of HDC, days to engraftment of absolute granulocyte count (the first of 3 consecutive days with AGC у500/l), platelet count (PLT у20 000l), nucleated cell (NC) dose, CFU-GM dose, and CD34
+ cell dose (available in only 34 patients). IBW was calculated by a standard formula using gender and height: for males, 50 kg + (2. 
PBSC collection and cryopreservation
PBSCs were mobilized after chemotherapy with G-CSF at 5 g/kg/day or with G-CSF alone at 10 g/kg/day. Different regimens of chemotherapy used for mobilization included doxorubicin or CAF for breast cancer and cytoxan with VP-16 or DHAP for patients with lymphoma. Leukapheresis began on day 5 if PBSC were mobilized with G-CSF alone and days 10-14 with a rising (Ͼ10 000/l) white blood count if chemotherapy and G-CSF were utilized. Approximately 50% and 90% of patients obtained the desired PBSC product with one or two pheresis procedures, respectively. The PBSC target was у2.5 × 10 6 CD34 + /kg or у5 × 10 8 NC/kg of ABW. Leukapheresis was performed using either a COBE-BCT Spectra (Lakewood, CO, USA) or a Baxter Fenwal CS3000 plus (Deerfield, IL, USA) according to the protocols for mononuclear harvesting as recommended by the manufacturers. Venous access was accomplished by a dialysis catheter inserted in the internal jugular vein such that high flow rates were obtained. Volumes processed ranged from 16 to 20 liters. PBSC were stored overnight and frozen the following day using a final concentration of 10% DMSO cryoprotective solution in a controlled rate freezer according to standard protocol.
Conditioning regimen
All patients were treated in-house with the STAMP V conditioning regimen which include cyclophosphamide, thiotepa and carboplatinum given by continuous infusion for 96 h. All patients received G-CSF at 5 g/kg/day from day +1, defined as the day after the PBSC infusion, and continued until engraftment of AGC у1500/l for 3 consecutive days. No other growth factors were utilized. Engraftment was defined as the first day of AGC у500/l following the nadir. Time to PLT recovery was defined as the number of days to reach an unsupported platelet count of greater than 20 000/l from day of PBSC infusion.
Evaluation of the PBSC graft
Each PBSC product was assessed for nucleated cell content (NC), and colony-forming units (CFU-GM). NC counts were performed on the products upon initial dilution and following the processing procedure. Counts were performed using the Sysmex F-800 (Baxter) employing Quicklyse (TOA Medical Electronics, Kobe, Japan) to lyse red blood cells as recommended by the manufacturer.
Clonogenic assays were performed on all PBSC products after thawing. A total of 10 5 NC per 1 ml aliquots of methylcellulose with PHA-LCM (Stem Cell Technologies, Vancouver, BC, Canada), were seeded in 35 mm Petri dishes and incubated for 12-14 days at 37°C in a fully humidified atmosphere containing 5% CO 2 . Aggregates of у50 cells were scored for CFU-GM, CFU-GEMM or BFU-E. Total CFU-GM dose was calculated according to NC counts. CD34 + enumeration was performed on the last 34 patients only, using flow cytometry on fresh samples obtained from each apheresis product. A set of three monoclonal antibodies for CD34, CD14 and CD45 (Becton 
Statistical methods
Patients were divided into low, intermediate and high cell dose groups for each of the three parameters used (NC, CFU-GM, CD34 + ), both calculated according to ABW or IBW. The AGC and PLT engraftment time rank sums were then compared among these groups using the Wilcoxon rank sum test. Nonparametric Low-ESS smoothing and 1/x linear regression (ie linear regression) using the inverse of the predictor variable were used to assess NC, CFU-GM, and CD34 (scaled by either ABW or IBW) as predictors of time to engraftment of AGC and PLT. The r 2 was used to indicate the strength of the linear association between the inverse of cell dose per kg ABW or IBW and day of engraftment. Cell dose and engraftment day 95% predictive intervals (PIs) at day 10 were estimated from corresponding linear regression lines. Finally, Cox proportional hazards regression was used to assess the influence of cell dose scaled by ABW or IBW on the probability of engraftment.
Results

Study population and patient exclusion
Initial linear regression model fitting indicated one patient to be highly influential with regard to NC and CD34 + parameter estimates. Upon review of this patient's stem cell product, although the initial PBSC harvest counts were high, the viability at the time of thawing and reinfusion was markedly reduced (12%) well out of the normal range (median of 76% on 30 consecutive PBSC samples other than those included in this study, range of 45-92%). The low PBSC viability appears to have prolonged this patient's engraftment significantly beyond what would be predicted by the NC and CD34
+ regression models with this patient excluded. This patient was therefore excluded from any further analyses. One other patient was excluded because of lack of information on his height needed for the calculation of IBW. Seven other patients were missing the exact time to engraftment of PLT or both PLT and AGC, and were excluded where appropriate.
Weight analysis
Our analysis of IBW shows that 49% of the patients were greater than 25% over their IBW. The median actual weight for all patients was 73 kg (range 44.3-109 kg), and the median IBW was 56.1 kg (range 43.8-75 kg).
Stem cell dose in relationship to engraftment
The target for collection was the total number of NC in the first 29 patients and the number of CD34 + cells/kg in the last 34 patients. Data on the CFU-GM and NC dose are available on all patients. A correlation between each of these parameters and the median time to engraftment of AGC and PLT is shown in Tables 2, 3 and 4. Table 2 shows correlation of the NC with engraftment. Patients were divided into three stem cell doses as shown in Table 2 . Four patients in group 1 were placed in group 2 when the stem cell dose was calculated by IBW. In addition, 11 patients in group 2 were ultimately placed in group 3 when their stem cell dose was calculated by IBW. As shown in Table  2 , engraftment of AGC and PLT in patients who changed groups when the stem cell dose was calculated by IBW tended to be very similar to those patients whose cell group did not change using ABW or IBW. Table 3 shows a correlation of CFU-GM content with engraftment. Again, patients were divided into three groups according to CFU-GM dose. Similarly seven and three patients were advanced from groups I and II (respectively) to the next cell dose group, when their cell dose was calculated per IBW. Table 4 shows a correlation of CD34 + cell content with engraftment. Patients were divided into three groups based on CD34 + cell dose. Two patients in group 1 by ABW changed to Group 2 when calculated by IBW and six patients in group 2 by ABW changed to group 3 when calculated by IBW. Patients who changed groups when calculated by IBW had similar engraftment characteristics to those patients where cell dose did not change with IBW or ABW.
IBW vs ABW effects on engraftment
Least-squares linear regression was used to assess the strength of the linear relationship between the inverse of cell dose/kg of ABW or IBW and time to AGC or PLT engraftment in the 63 study patients. Using dose/kg of IBW greatly improved the ability of NC and CFU-GM to predict time to AGC engraftment relative to dose/kg of ABW, see An attempt to analyze the whole group of transplanted patients (n = 14), as mentioned in Materials and methods, the r 2 values obtained were consistently less than 0.1 indicating the great heterogeneity in this patient population. However, when the relationship between the cell dose/kg of ABW or IBW and time to AGC and PLT engraftment was assessed as described above, the r 2 values showed improvement in favor of IBW. For example, the CD34 r 2 (n = 86) for AGC engraftment improved from 0.041 for ABW to 0.052 for IBW. There was a greater improvement seen in the r 2 for NC and CFU-GM dose calculated by IBW.
Hazard ratios were estimated using Cox proportional Three different groups of NC dose were analyzed. n = number of patients; P25 = 25th percentile; P75 = 75th percentile.
a Significantly lower than group I (P Ͻ 0.05).
b Significantly higher than group III (P Ͻ 0.05). Three different groups of CFU-GM dose were analyzed. n = number of patients; P25 = 25th percentile; P75 = 75th percentile.
a Significantly lower than group 1 (P Ͻ 0.05).
b Significantly higher than group III (P Ͻ 0.05). Three different groups of CD34 + cell dose were analyzed. n = number of patients; P25 = 25th percentile; P75 = 75th percentile. a Significantly lower than group 1 (P Ͻ 0.05). b Significantly higher than group III (P Ͻ 0.05). A = actual body weight; I = ideal body weight; PI = prediction interval.
hazards regression. The hazard ratio is interpretable as the factor by which the probability of engraftment changes per unit increase in cell dose. Dose units for NC, CFU-GM and CD34 + are defined here as 1 × 10 8 , 5 × 10 4 and 1 × 10 6 , respectively. When analyzing the 63 study patients, hazard ratios, in all instances, were greater than 1.0 indicating that the probability of engraftment increased as cell dose per kg ABW or IBW increased.
Potential savings using IBW
In order to evaluate potential cost savings, we identified patients that switched to a different cell dose grouping as defined in Tables 2, 3 and 4 when their cell dose was calculated by IBW vs ABW. Among those patients three, seven and three patients (total of 10 patients due to overlap) of the CD34
+ , NC and CFU-GM groups, respectively, could have had one less procedure to achieve the desired stem cell dose calculated per kg IBW. Other patients who switched groups when their stem cell product was calculated using IBW vs ABW had only one apheresis procedure to obtain their desired stem cell dose and therefore cost savings were not applicable to them. Thus, 10 of the 63 patients (16%) could have had one less procedure performed to obtain their target stem cell dose, ie у3 × 10 
Discussion
Autologous blood stem cell transplantation to support highdose chemotherapy is now commonplace in the treatment of lymphomas and solid tumors including breast cancer. The advantages of PBSC collections include the ability to attain a greater number of stem cells compared to bone marrow harvest, which results in shorter duration of neutropenia and platelet engraftment and therefore shortens hospital stay and reduces the number of red cell and platelet transfusions. [3] [4] [5] [6] Other advantages of PBSC include reduced tumor contamination in PBSC products [30] [31] [32] and the ability to perform tandem transplants. 33 However, harvesting adequate numbers of CD34 + cells for autologous transplantation can be difficult in some patients that are, due to different reasons, 'poor mobilizers' of CD34 + cells into the peripheral blood. These patients usually require higher numbers of leukaphereses and other manipulations which can easily exceed the cost of BM harvest. Improvements in the evaluation of the stem cell products have increased our ability to predict rapid hematopoietic engraftment of both neutrophils and platelets. However, improvements in the evaluation of the stem cell products have been focused on qualitative measurements of the transplanted cells, and to our knowledge there are no data evaluating the effect of weight, ideal vs actual, on the ability of the stem cell product to predict engraftment. In many transplant centers, chemotherapy and other drugs are calculated based on IBW, however, most centers use ABW in the calculation of the stem cell dose. In this study, we evaluated the precision of stem cell dose stratified for IBW vs ABW to predict engraftment of both AGC and PLT count. We found that calculation of the stem cell dose per IBW was equal to or superior in predicting hematopoietic engraftment for both AGC and platelet count when compared to a stem cell product calculated by ABW. Our patient population mirrored the general population with over 40% considered to be greater than 25% over their IBW. Therefore, a significant percentage of our patients will have large disparities in their calculated stem cell dose when comparing IBW to ABW. Since the stem cell dose relationship to days to engraftment has been well established and produces hyperbolic-shaped curves, we can expect that adjustments to IBW will affect a significant portion of patients.
Increasing the cell dose above 5 × 10 6 CD34 cells/kg of body weight may shorten duration of thrombocytopenia but does not shorten duration of neutropenia any further. There appears to be a ceiling on the cell dose on which further stem cell collection has little or no benefit. 1, 2, 20 Furthermore, patients who are very good mobilizers may not benefit from adjusting cell dose from ABW to IBW since the desired cell dose will usually be obtained with one apheresis procedure. Similarly, when the stem cell dose is below 1 × 10 6 CD34 + cells/kg, engraftment is typically poor and more sporadic, and therefore, switching the calculation from ABW to IBW may have no benefit. However, there may be a significant cost saving and reduction in morbidity by limiting the number of pheresis procedures necessary to obtain the desired stem cell dose for some patients who are good mobilizers and overweight. In our study, 48% of patients required only one pheresis procedure to obtain the desired stem cell dose. However, as reported in Results, 16% of the patients could have had one less procedure to attain the desired stem cell product, if the cell dose was calculated per IBW. Therefore, by simply calculating the stem cell dose by IBW, we can maintain equal or improved precision in the ability to predict rapid hematopoietic recovery of both AGC and PLT as well as reduce morbidity and cost in a small but significant proportion of the patients undergoing peripheral blood stem cell transplantation.
Owing to the retrospective nature of our study and the relatively limited number of patients with CD34
+ data available, future prospective studies may be needed in order to verify our results and conclusions. Evaluating the effects of body weight in the future may be even more significant, mainly because many centers have increased their target stem cell dose to у5 × 10 6 CD34 + cells/kg, a dose that has been shown to be cost effective by ensuring rapid engraftment and reducing platelet transfusion costs. Our results suggest that adjusting stem cell dose in this range for IBW or ABW may not show a statistical difference; however, reaching this target range using IBW may prevent additional apheresis in a small but significant number of patients that are overweight and thus reducing the cost of PBSC harvesting, without affecting the time to engraftment. Based on our results, the target cell dose at our institution is currently у5 × 10 6 CD34 + cells/kg of IBW.
